Target intelligence / Profile preview

Rabies Virus Glycoprotein Epitope III

Molecular classification: Epitope, Viral Protein Epitope

Overview

Rabies virus glycoprotein (RABV-G) epitope III is a linear epitope located between amino acids 330–338 of the RABV-G protein. It is a major antigenic site recognized by neutralizing monoclonal antibodies and plays a significant role in inducing protective immunity against rabies infection. Antibodies targeting epitope III are highly effective at neutralizing rabies virus. Changes within this region can affect antibody binding and potentially alter viral pathogenicity or immune escape mechanisms.

Other names: Epitope IIIAntigenic Site III

Mechanism of action

Neutralization of viral entry

Biological functions

Neutralizing antibody targetInduction of protective immunityViral neutralization

Disease associations

Infection

Beyond the preview

Go deeper on Rabies Virus Glycoprotein Epitope III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabies Virus Glycoprotein Epitope III.

Explore the full profile